This scientific advisory advisory agreement (`agreement`) will be concluded on June 1, 2020 between Stoke Therapeutics, Inc., a Delaware company with offices at 45 Wiggins Avenue, Bedford, MA 01730 (“Stoke”) and Adrian Krainer, Ph.D. (“Advisor”). The consultant has unique skills and knowledge that are relevant to Stoke`s operations and Stoke wishes to retain Advisor as a member of the Stoke Scientific Committee (“SAB”) under the terms of the agreement. CET ACCORD (the “agreement”) of May 1, 2006 (“Date of effect”) is concluded by and between Medgenics, Inc. at 8000 Towers Crescent Drive, Suite 1300, Vienna, VA, 22182. The United States. This amendment to the Scientific Advisory Board (“Amendment”) agreement will be completed on July 21, 2011 (“Execution Date”) by and between Dr. Joe M. McCord, Ph.D., and LifeVantage Corporation, a Colorado company (the “company”). THIS NUMBER OF AMENDMENT NO 1 ZU WISSENSCHAFTLICHEN ADVISORY BOARD AGREEMENT (die “nderung”) dates from September 21, 2016 between Enumeral Biomedical Holdings, Inc., a Delaware company (with its subsidiaries, the “Company”), and Barry Buckland, Ph.D. (the “consultant”). This amendment amends the fact that a specific agreement on the Scientific Advisory Committee, dated 14 September 2014, was concluded by and between the company and the advisor (the “DEE Agreement”). The wholesale words that are used here, but which are not defined differently, must have the meanings attributed to these terms in the SAB agreement.
This scientific agreement (the “agreement”) will be concluded on February 28, 2020 between Moleculin Biotech, Inc. (the “company”) and Waldemar Priebe, PhD (the “scientific advisor”). This ADVISORY BOARD AGREEMENT takes effect on January 1, 2015 (effective date) of and between E-QURE Corp, a (the company) and Prof. Avi Ohry (the “adviser”). . SCIENTIFIC ADVISORY BOARD AGREEMENT, dated June 10, 2011, from and between NAIYER IMAM, M.D., with an address at 6185 Steeplechase Drive, Roanoke, Virginia, and STEM CELL ASSURANCE, INC., a Nevada company (the “company”), with offices on 555 Heritage Drive, Suite 130, Jupiter, Florida 33458. September 19, 2018 (effective date), between Pyramidian Technology Group, Inc., or (“PYTG”) with its main location at 2645 Executive Park Drive Drive , Suite163 Weston, FL 33331 “Company”), a Nevada company and . CET ACCORD (the “agreement”) was concluded on 24 December 2013 (effective date) between Lixte Biotechnology Holdings, Inc., 248 Route 25A No.
2, East Setauket, New York 11733 (`company`) and NDA Consulting Corp., an Arizona-based company with offices at 9977 N. 90th Street, Suite 175, Scottsdale, Arizona 85258 (`Consultant`.